MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.
She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.
MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.
The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.
On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."
The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.
This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.
A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.
These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.
Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:
The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.
It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.
In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.
This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.
Credit: AI-generated image
Russia has reported a milestone in its experimental personalised cancer vaccine development. The first patient to complete treatment with the country's mRNA-based cancer vaccine is reportedly doing well as the follow-up scans showed no new tumour growth in the four months after completing therapy.
The update was shared by Alexander Gintsburg, scientific director of Moscow's Gamaleya Research Institute of Epidemiology and Microbiology.
According to a report published by Kursiv, the patient is undergoing monthly examinations at Russia's National Medical Research Centre for Radiology, including high-resolution CT scans. Doctors are paying attention to the lymph nodes where cancer is most likely to spread.
The patient will remain under medical observation for the next three years. While the early findings are promising, they are based on a single patient's experience, which is a major limitation.
Also read: How The Conditions People Live In Can Quietly Shape Our Risk Of Cancer
The treatment, known as NeoOncovac, is a personalised cancer vaccine developed with the help of messenger RNA (mRNA) technology.
Unlike preventive vaccines that protect people against infections, therapeutic cancer vaccines are designed to help the immune system recognise and attack existing cancer cells.
The vaccine is customised using the genetic characteristics of an individual's tumour. Researchers analyse tumour samples to identify specific mutations that could help distinguish cancer cells from healthy cells.
The mRNA is then designed to instruct the body to produce these targets related to tumour, prompting the immune system to recognise and attack the cancer cells. It aims to make the immune response more specific to the patient's cancer rather than targeting all cancer cells.
Also read: American Cancer Society Revises Prostate Cancer Screening Guidelines: What You Need To Know
According to reports citing Gintsburg, six patients with melanoma have received the personalised vaccine so far. The first has completed the treatment course, while the second is reportedly halfway through a course involving 10 administrations. Four other patients have also begun treatment.
Russian specialists expect to treat around 20 patients at the Herzen Moscow Research Institute of Oncology by the end of 2026. The country's Health Ministry has reportedly allocated funding for the treatment and follow-up of 120 patients during 2026 and 2027.
Even though the findings are promising, they should not be interpreted as evidence of a cancer cure. The current update concerns one patient with melanoma, a type of skin cancer. Although doctors have reported no new tumour growth during the follow-up period, four months is too short to establish whether the response will last or whether the cancer could return.
There are also currently no results from a large controlled clinical trial that could establish the vaccine's effectiveness, long-term safety or survival benefit.
Outcomes across more patients will be essential to determine whether the treatment can consistently produce similar results.
Personalised cancer vaccines are an active area of research internationally. In October 2026, Moderna and Merck reported positive late-stage trial findings for their experimental personalised mRNA melanoma vaccine, used alongside the immunotherapy drug pembrolizumab (Keytruda).
The trial involved more than 1,100 patients and found a reduction in the risk of melanoma recurrence or death compared with Keytruda alone. However, this is a different vaccine and treatment from Russia's NeoOncovac.
Credit: AI-generated image
In a major milestone in fetal and paediatric neurosurgery in India, doctors at the All India Institute of Medical Sciences (AIIMS), New Delhi, have performed the country's first open fetal surgery to repair myelomeningocele, the most severe form of spina bifida.
The six-hour procedure was carried out at 25 weeks of pregnancy, in which surgeons were able to repair the baby's spinal defect before birth. The surgery, performed on November 12, entailed repairing a cerebrospinal fluid leak in the lower back while the baby was still in the uterus.
According to AIIMS press release, the operation followed more than five weeks of preparation in multiple disciplines, including detailed fetal imaging, counselling, planning anaesthesia and surgical simulations.
The procedure was done by more than 30 clinicians and nurses from neurosurgery, maternal-fetal medicine, obstetrics, anaesthesia, plastic surgery, radiology and neonatology.
Professor PS Chandra, Head of Neurosurgery at AIIMS, who facilitated the entire surgical execution by the neurosurgery team, said that prenatal surgery could help reduce the incidence of hydrocephalus and Chiari malformations linked with spina bifida.
Myelomeningocele is an open neural tube defect in which the spinal cord and its protective coverings protrude through an opening in the developing spine. It occurs when the neural tube, which eventually develops into the brain and spinal cord, does not close completely during early pregnancy.
The condition can cause permanent nerve damage, muscle weakness or paralysis, loss of bladder and bowel control, and complications involving the brain and spinal cord. Some affected babies also develop hydrocephalus, a condition in which excess cerebrospinal fluid accumulates in the brain.
In many cases, surgery to close the spinal defect is performed after birth. However, exposure of the spinal cord to the surrounding amniotic fluid during pregnancy can contribute to further neurological injury.
India continues to face a burden of neural tube defects. A 2024 review of 27 Indian studies estimated their pooled prevalence at 9.46 per 1,000 births.
Also read: India’s Xenotransplantation Push: Can Pig Organs Help Bridge the Organ Shortage? | Interview
Unlike conventional postnatal surgery, open fetal repair involves operating on the fetus while it is still inside the uterus. The surgeon accesses the uterus, exposes the affected area of the baby's spine and closes the defect, protecting the exposed spinal cord and its coverings. The aim is to limit further damage to the developing nervous system and improve certain neurological outcomes.
Professor Deepak Gupta, who led the neurosurgical part of the procedure, said, “This establishes an important new capability for fetal care and paediatric neurosurgery in India. In rigorously selected cases, prenatal repair seeks to limit ongoing injury to exposed neural tissue, reduce the subsequent need for cerebrospinal-fluid diversion for hydrocephalus, and improve selected neurological outcomes. It is not a cure, and long-term multidisciplinary care remains essential.”
Evidence for prenatal repair comes from the landmark Management of Myelomeningocele Study (MOMS), an international clinical trial. It found that 40% of children who underwent prenatal surgery required a cerebrospinal fluid shunt by 12 months of age, compared to 82% of those who underwent surgery after birth. Prenatal repair also helped with better motor outcomes and a lower incidence of hindbrain herniation linked with Chiari II.
But fetal surgery comes with its risks. It can increase the chances of premature delivery. It also carries risks related to the opening and subsequent healing of the mother's uterus. It is therefore performed only on carefully selected pregnancies at specialised centres equipped with resources.
The AIIMS procedure brings a complex fetal intervention, which is already done in other countries, to India's public healthcare system.
Professor Neena Malhotra, who led the maternal-fetal medicine and obstetric part of the surgery alongside Professor K Aparna Sharma, said, “This accomplishment reflects the collective commitment of an exceptional multidisciplinary team.”
Professor Sharma added, “Fetal intervention in this case is a very well-reasoned and planned decision to optimise the outcomes of both the baby and the mother. The safety of both mother and fetus depends on detailed counselling, high-quality anaesthesia, and coordinated surveillance before and after surgery.”
AIIMS said the procedure was performed free of cost under the Government of India's Janani Shishu Suraksha Karyakram (JSSK). The mother and fetus will continue to receive close monitoring throughout the remainder of the pregnancy, delivery and newborn period.
Also read: First Human Spinal Cord Transplant Reported In Russia But Can It Reverse Paralysis?
Prevention of spina bifida remains essential even though the option of fetal surgery is available. Neural tube closure takes place within the first 28 days after conception, often before a woman realises she is pregnant.
Adequate folic acid intake before conception and during early pregnancy can significantly reduce the risk of neural tube defects. Preconception counselling, folic acid intake and dietary interventions with folate are therefore important to prevent spina bifida.
Credit: AI-generated image
The World Health Organization (WHO) has issued its first-ever guidelines for the diagnosis and management of type 1 diabetes in adults. The recommendations aim to improve insulin access and blood glucose monitoring in countries where healthcare resources are limited.
Released on November 14 to mark World Diabetes Day 2026, the guidelines cover insulin treatment, blood glucose monitoring and care in emergency and humanitarian settings. They are meant to help healthcare providers deliver safer treatment, regardless of the resources available.
The guidelines come as the global burden of type 1 diabetes continues to grow. In 2025, 500,000 people were diagnosed with type 1 diabetes, adding to an estimated 9.5 million people living with the condition worldwide in 2025, according to the WHO. Although type 1 diabetes is often diagnosed during childhood, it can develop at any age, including adulthood.
Also read: Effect of Diabetes on Different Organs: Why the Damage Is Not the Same Everywhere
A primary recommendation is intensified insulin treatment through multiple daily injections, along with the doses adjusted according to blood glucose levels. People with type 1 diabetes cannot produce enough insulin and therefore need lifelong insulin therapy to survive.
The guidelines recognise insulin as an effective and affordable treatment option. Insulin analogues, which are modified forms of insulin designed to alter how long the medicine works, may also be used when needed. The guidelines also address how treatment and monitoring can be adapted in low-resource settings and during emergencies.
The recommendations also emphasise regular blood glucose monitoring.
Also read: World Diabetes Day 2026: Is India's Toxic Air Adding To Its Diabetes Crisis? What Experts Say
More than a century after insulin was discovered, access to affordable treatment remains a challenge for many people with type 1 diabetes. Interruptions in insulin supply can be life-threatening because the body depends on externally administered insulin to regulate blood glucose.
Without enough insulin, blood glucose can rise dangerously and lead to diabetic ketoacidosis (DKA), a fatal complication.
“Insulin is a lifesaving treatment, discovered more than 100 years ago. Yet many people with type 1 diabetes do not have access to affordable and high-quality insulin,” said Dr Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health.
“The new WHO guidelines provide evidence-based recommendations to help countries deliver the best possible care, including in settings where resources are limited and health services are disrupted.”
The WHO guidelines aim to reduce these gaps by providing recommendations that can be implemented across different healthcare systems, including those with limited resources. They also support the organisation's bigger target of ensuring universal access to affordable insulin treatment and blood glucose self-monitoring by 2030.
The WHO has encouraged countries to involve people living with type 1 diabetes in designing diabetes programmes, so that they reflect practical challenges patients face.
Type 1 diabetes is an autoimmune condition in which the immune system destroys the insulin-producing beta cells in the pancreas. Unlike type 2 diabetes, it is not primarily caused by insulin resistance or lifestyle factors.
People with the condition need lifelong insulin treatment, alongside regular glucose monitoring and medical follow-up. Without appropriate management, diabetes can lead to complications affecting the eyes, kidneys, nerves and cardiovascular system.
© $2026 Times Horizon Private Limited